Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Pyoderma Gangrenosum in Patients with Palmoplantar Pustulosis Treated with Brodalumab: A Case Series.

Created on 16 Nov 2026

Authors

Yukari Okubo, Satomi Kobayashi, Masamoto Murakami, Taiki Udagawa, Junichi Furuta, Ryoko Shimada-Omori, Maiko Kato, Ryusuke Ono, Kenta Shishido, Tadashi Terui

Published in

Dermatology and therapy. Nov 15, 2026. Epub Nov 15, 2026.

Abstract

Brodalumab is approved for the treatment of palmoplantar pustulosis (PPP)-a chronic, immune-mediated skin disease-in Japan. A recent phase 3 randomized clinical trial and its open-label extension evaluated the long-term efficacy and safety of brodalumab over 68 weeks, in Japanese patients with PPP. This case series details the cases of pyoderma gangrenosum (PG), a rare, neutrophilic dermatosis, that were reported during the trial.
Clinical and histopathological findings were reviewed for five patients with PPP who developed PG during or after brodalumab treatment in the phase 3 trial and its 68-week extension.
All affected patients were female and aged 40-70 years without any other PG-associated medical conditions. Development of PG was observed at 61-345 days after treatment initiation. Brodalumab was discontinued after onset of PG, except in case 3. Prednisolone treatment was administered, except in case 4, with all cases showing improvement.
PG may present as a rare condition in patients receiving brodalumab for PPP; the detailed mechanisms remain unclear, but early recognition and appropriate management is crucial.
The open-label extension study was registered as NCT04061252.

PMID:
43034958
Bibliographic data and abstract were imported from PubMed on 16 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 13
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement